Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 17;15(22):5453.
doi: 10.3390/cancers15225453.

Enhancing Cervical Cancer Prevention in South African Women: Primary HPV mRNA Screening with Different Genotype Combinations

Sveinung Wergeland Sørbye  1 , Bente Marie Falang  2 , Matthys H Botha  3 , Leon Cornelius Snyman  4 , Haynes van der Merwe  3 , Cathy Visser  4 , Karin Richter  5 , Greta Dreyer  4
Affiliations

Enhancing Cervical Cancer Prevention in South African Women: Primary HPV mRNA Screening with Different Genotype Combinations

Sveinung Wergeland Sørbye et al. Cancers (Basel). .

Abstract

Background: Cervical cancer prevention in regions with limited access to screening and HPV vaccination necessitates innovative approaches. This study explored the potential of a test-and-treat strategy using mRNA HPV tests to impact cervical cancer prevention in a high-prevalence HIV population.

Methods: A cervical screening study was conducted at three South African hospitals involving 710 under-screened, non-pregnant women (25 to 65 years) without known cervical diseases. Cytology, HPV testing, colposcopy, and biopsies were performed concurrently. Histopathologists determined final histological diagnoses based on biopsy and LLETZ histology. mRNA-HPV-genotyping for 3 (16, 18, 45) to 8 (16, 18, 31, 33, 35, 45, 52, 58) high-risk types was performed on leftover liquid-based cytology material. The preventive potential of the test-and-treat approach was estimated based on published data, reporting the causative HPV types in cervical cancer tissue from South African women. Treatment was provided as needed.

Results: The HPV positivity rate more than doubled from 3-type (15.2%; 95% CI: 12.6-17.8) to 8-type mRNA (31.5%; 95% CI: 28.8-34.9) combinations, significantly higher among HIV-positive women. CIN3+ prevalence among HIV-positive women (26.4%) was double that of HIV-negative women (12.9%) (p < 0.01). The 6-type combination showed the best balance of sensitivity, specificity and treatment group size, and effectiveness to prevent cervical cancer. A 4-type combination (16, 18, 35, 45) could potentially prevent 77.6% (95% CI: 71.2-84.0) of cervical cancer burden by treating 20% and detecting 41.1% of CIN3 cases in the study group. Similarly, a 6-type combination (16, 18, 31, 33, 35, 45), treating 25% and including 62% of CIN3 cases, might prevent 85% of cervical cancer cases (95% CI: 79.6-90.6) among HIV-positive and negative women.

Conclusion: Employing mRNA HPV tests within a test-and-treat approach holds huge promise for targeted cervical cancer prevention in under-screened populations. Testing for mRNA of the 6 highest-risk HPV types in this population and treating them all is projected to effectively prevent progression from CIN3 to invasive cervical cancer while reducing overtreatment in resource-constrained settings.

Keywords: HIV interaction; HPV screening; cervical cancer; global health challenges; human papillomavirus; negative predictive value; number needed to treat; positive predictive value; prevention strategies; risk management; “Test and Treat” approach.

PubMed Disclaimer

Conflict of interest statement

Author Bente Mare Falang was employed by the company PreTect AS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overview selection of study population.
See this image and copyright information in PMC

References

    1. Safaeian M., Solomon D. Cervical cancer prevention—Cervical screening: Science in evolution. Obstet. Gynecol. Clin. N. Am. 2007;34:739–760. doi: 10.1016/j.ogc.2007.09.004. - DOI - PMC - PubMed
    1. Franco E.L., Mahmud S.M., Tota J., Ferenczy A., Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: The need for a paradigm change. Arch. Med. Res. 2009;40:478–485. doi: 10.1016/j.arcmed.2009.06.003. - DOI - PubMed
    1. Herzog T.J., Huh W.K., Einstein M.H. How does public policy impact cervical screening and vaccination strategies? Gynecol. Oncol. 2010;119:175–180. doi: 10.1016/j.ygyno.2010.08.021. - DOI - PMC - PubMed
    1. Petersen Z., Jaca A., Ginindza T.G., Maseko G., Takatshana S., Ndlovu P., Zondi N., Zungu N., Varghese C., Hunting G., et al. Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: A systematic review. BMC Womens Health. 2022;22:486. doi: 10.1186/s12905-022-02043-y. - DOI - PMC - PubMed
    1. World Health Organization Global Strategy towards the Elimination of Cervical Cancer as a Public Health Problem. 2020. [(accessed on 17 March 2022)]. Available online: https:/ijgc.bmj.com/content/ijgc/early/2020/03/02/ijgc-2020-0011285.full....

LinkOut - more resources